Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_8
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.16.044016 doi: bioRxiv preprint characterized 7 compounds that exhibit a range of effective concentrations (EC 50 ) that are consistent with potential clinical efficacy. These include a PIKfyve kinase inhibitor that has reached Phase II clinical trials (Apilimod), and cysteine protease inhibitors (MDL-28170, Z LVG CHN2, VBY-825, and ONO 5.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.16.044016 doi: bioRxiv preprint characterized 7 compounds that exhibit a range of effective concentrations (EC 50 ) that are consistent with potential clinical efficacy. These include a PIKfyve kinase inhibitor that has reached Phase II clinical trials (Apilimod), and cysteine protease inhibitors (MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334) that are in various phases of preclinical and clinical development. In addition, the preclinical ion channel blocker AMG-2674 and the ion channer blocker and antimalarial drug hanfangchin A, the phase I proton pump inhibitor YH-1238, as well as the G-protein receptor antagonists MLN-3897 and SDZ-62-434 35 , which are in phase II and phase I clinical evaluation respectively, were also found to possess antiviral activity against SARS-CoV-2. Rapid experimental and clinical evaluation of these therapeutics for in vivo antiviral efficacy and amelioration of disease-associated pathologies can provide an important opportunity for the accelerated development of potential therapies for COVID-19 treatment.
Search related documents:
Co phrase search for related documents- accelerated development and clinical evaluation: 1, 2, 3
- accelerated development and clinical preclinical development: 1, 2, 3
- accelerated development and clinical trial: 1, 2, 3, 4
- antiviral activity and clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and clinical evaluation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and cysteine protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antiviral activity and cysteine protease inhibitor: 1
- antiviral activity and effective concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral efficacy and clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral efficacy and clinical evaluation: 1, 2, 3, 4, 5, 6
- antiviral efficacy and clinical preclinical development: 1
- antiviral efficacy and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral efficacy and cysteine protease: 1, 2
- antiviral efficacy and cysteine protease inhibitor: 1
- antiviral efficacy and effective concentration: 1, 2, 3, 4, 5, 6
- clinical efficacy and cysteine protease: 1
- clinical efficacy and effective concentration: 1, 2, 3, 4
- clinical evaluation and cysteine protease: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date